Cell based Assays Market worth $28.2 billion by 2028 | Danaher Corporation (US), Thermo Fisher Scientific (US), Merck (Germany), Becton, Dickinson and Company (US)

The report "Cell based Assays Market by Product & Service (Reagents, Assays Kits, Cell Lines, Microplates, Probes & Labels, Instruments & Software), Application (Drug Discovery (Toxicity, Pharmacokinetics), Research), End User (CROS, Pharma) - Global Forecast to 2028", is projected to reach USD 28.2 billion by 2028 from USD 18.9 billion in 2023, at a CAGR of 8.4% during the forecast period of 2023 to 2028.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=119917269&utm_source=Openpr&utm_campaign=Paid&utm_content=Referral

The global cell-based assays market is expected to grow at a CAGR of 8.4% during the forecast period. The market for cell-based assays is experiencing significant growth primarily due to the increasing demand for drug discovery and development, as well as the rising adoption of cell-based assays in this process. Government support and funding for cell-based research initiatives are further contributing to this growth. Additionally, efforts by regulatory authorities, such as the FDA, to reduce reliance on animal-based studies are driving the adoption of cell-based assays.

The instruments and software segment accounted for the second largest share, by product and service in the cell-based assays market in 2022.

These sophisticated instruments enable researchers to automate and streamline various aspects of cell-based assays, enhancing efficiency, accuracy, and throughput. Additionally, powerful software platforms provide advanced data analysis, visualization, and integration capabilities, enabling researchers to derive valuable insights from their experiments. The integration of cutting-edge instruments and software solutions into cell-based assays research workflows is revolutionizing the field and propelling the market forward.

The pharmaceutical & biopharmaceutical companies segment accounted for the largest share of the end user segment in the cell-based assays market in 2022.

The pharmaceutical & biopharmaceutical companies dominated the market in 2022. Pharmaceutical & biopharmaceutical companies are the largest end users of cell-based assays. The demand for cell-based assays in this end-user segment is driven by the growth in the number of R&D activities for the development of new pharma and biotech drugs and therapies coupled with the adoption of cell-based assays in these companies.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=119917269&utm_source=Openpr&utm_campaign=Paid&utm_content=Referral

The North America region catered the largest share of the cell-based assays market in 2022.

North America has emerged as the dominant region in the cell-based assays market. The region's leadership can be attributed to several factors, including a robust pharmaceutical and biotechnology industry, extensive research and development activities, and a favorable regulatory environment. Furthermore, the presence of key market players, advanced healthcare infrastructure, and significant investments in drug discovery and development contribute to North America's strong market position. The region's emphasis on technological advancements and the adoption of innovative approaches in cell-based assays further solidifies its dominance in the market..

Key Market Players

Key players in the cell-based assays market include Danaher Corporation (US), Thermo Fisher Scientific (US), Merck (Germany), Becton, Dickinson and Company (US), Lonza (Switzerland), PerkinElmer (US), Charles River Laboratories (US), Eurofins Scientific (France), Enzo Biochem (US), Carna Biosciences (Japan), Cell Biolabs (US), Promega Corporation (US), Cell Signaling Technology (US), BioAgilytix Labs (US), Reaction Biology Corporation (US), AAT Bioquest (US), Pestka Biomedical Laboratories (US), InvivoGen (US), CA3 Biosciences (US), BPS Bioscience (US), BellBrook Labs (US), Profacgen (US), BMG LABTECH (Germany), Hanugen Therapeutics (India), and JRS Pharma (Germany).

Cell-based assays Market- Report Highlights:

The market size is updated for the base year 2022 and forecasted from 2023 to 2028 by studying the impact of the recession on the overall cell-based assays industry.

The new edition includes the impact of the recession on the cell-based assays market (especially the region-wise impact in the geographic analysis section) in 2022. There is a variation in the growth rate of the market due to the ongoing recession.

Additional points such as, impact of uncertainties on cell-based assays market, trends/disruptions impacting customers' businesses, pricing analysis, patent analysis, key conferences and events (2022-2023), list of key regulatory bodies, regulatory landscape, Porter's Five Forces analysis, key stakeholders, the influence of stakeholders on buying decisions, and buying criteria among end users have been added in the market overview chapter.

The Latin American region is split into Brazil and the Rest of Latin America. The Middle East & Africa is further split into the Middle East and Africa. This has been newly added in the geographical analysis section of the current edition of the cell-based assays market report.

Recent developments are helpful to know the market trends and growth strategies adopted by players in the market.

Tracking product portfolios helps analyze the cell-based assay offerings in the market. The new edition of the report provides an updated product & service portfolio of the companies profiled in the report.

Additional company profiles have been added (a total of 25 companies profiled).

Key market strategies/right to win and competitive benchmarking been added in the competitive landscape section of the current edition of the cell-based assays market report.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=119917269&utm_source=Openpr&utm_campaign=Paid&utm_content=Referral

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/cell-based-assays-market.asp
Visit Our Website: https://www.marketsandmarkets.com/
Content Source: https://www.marketsandmarkets.com/PressReleases/cell-based-assays.asp

About MarketsandMarkets™:

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

This release was published on openPR.